Literature DB >> 11008112

Version 2000: the new beta-lactamases of Gram-negative bacteria at the dawn of the new millennium.

K S Thomson1, E Smith Moland.   

Abstract

beta-lactamases of Gram-negative bacteria are evolving dynamically. New developments include the production of enzymes with novel substrate profiles, reduced susceptibility to beta-lactamase inhibitors, and the simultaneous production of multiple types of beta-lactamases. The changes represent evolutionary upgrades which provide modern pathogens with a greater potential to resist beta-lactam antibiotics and cause formidable therapeutic, infection control, and diagnostic challenges. This review is a clinically oriented outline of recent developments in the beta-lactamase production of Gram-negative bacteria.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11008112     DOI: 10.1016/s1286-4579(00)01276-4

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  24 in total

1.  BetalasEN: microdilution panel for identifying beta-lactamases present in isolates of Enterobacteriaceae.

Authors:  Christine C Sanders; Anton F Ehrhardt; Ellen Smith Moland; Kenneth S Thomson; Barbara Zimmer; Darcie E Roe
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

2.  Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR.

Authors:  F Javier Pérez-Pérez; Nancy D Hanson
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

3.  In vitro and in vivo activities of AM-112, a novel oxapenem.

Authors:  Conor E Jamieson; Peter A Lambert; Iain N Simpson
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

4.  Prevalence of clinical isolates of Escherichia coli producing inhibitor-resistant beta-lactamases at a University Hospital in Barcelona, Spain, over a 3-year period.

Authors:  Elisenda Miró; Ferran Navarro; Beatriz Mirelis; Montserrat Sabaté; Alba Rivera; Pere Coll; Guillem Prats
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

5.  Occurrence of newer beta-lactamases in Klebsiella pneumoniae isolates from 24 U.S. hospitals.

Authors:  Ellen Smith Moland; Jennifer A Black; Jason Ourada; Mark D Reisbig; Nancy D Hanson; Kenneth S Thomson
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

6.  Extended-spectrum beta-lactamases in Ireland, including a novel enzyme, TEM-102.

Authors:  Dearbháile Morris; Colette O'Hare; Maura Glennon; Majella Maher; Geraldine Corbett-Feeney; Martin Cormican
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

7.  Model system to evaluate the effect of ampD mutations on AmpC-mediated beta-lactam resistance.

Authors:  Amber J Schmidtke; Nancy D Hanson
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

8.  Comparision of Three Laboratory Tests for Detection of AmpC β Lactamases in Klebsiella Species and E. Coli.

Authors:  D L Maraskolhe; V S Deotale; D K Mendiratta; P Narang
Journal:  J Clin Diagn Res       Date:  2014-06-20

Review 9.  Strategic Moves of "Superbugs" Against Available Chemical Scaffolds: Signaling, Regulation, and Challenges.

Authors:  Bikash Baral; M R Mozafari
Journal:  ACS Pharmacol Transl Sci       Date:  2020-04-13

10.  In vitro activities of novel oxapenems, alone and in combination with ceftazidime, against gram-positive and gram-negative organisms.

Authors:  Conor E Jamieson; Peter A Lambert; Iain N Simpson
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.